Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts

Inflammatory Bowel Diseases

Volumn 16, Issue 9, 2010, Pages 1505-1513

  Rieder, Florian ^a,b   Georgieva, Martina ^a   Schirbel, Anja ^b   Artinger, Monika ^a   Zügner, Anita ^a   Blank, Martin ^a   Brenmoehl, Julia ^c   Schölmerich, Jürgen ^a   Rogler, Gerhard ^d  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

^c LEIBNIZ INSTITUTE FOR FARM ANIMAL BIOLOGY FBN   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Crohn's disease; Fibroblast; Fibrosis; Migration; PGE2

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ALPHA SMOOTH MUSCLE ACTIN; CYCLIC AMP; F ACTIN; FORSKOLIN; MYOSIN LIGHT CHAIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; LAMINA PROPRIA; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WOUND HEALING;

BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; COLON; CYCLIC AMP; DINOPROSTONE; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MUCOUS MEMBRANE; OXYTOCICS; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; WOUND HEALING;

EID: 77956286245     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21255     Document Type: Article

References (43)

1. Rieder F, Brenmoehl J, Leeb S, et al. Wound healing and fibrosis in intestinal disease. Gut. 2007;56:130-139. (Pubitemid 46044899)
2. Rieder F, Fiocchi C. Intestinal fibrosis in IBD - a dynamic, multifactorial process. Nat Rev. 2009;6:228-235.
3. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol. 2000;279:G653-659.
4. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250. (Pubitemid 34784976)
5. Leeb SN, Vogl D, Gunckel M, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology. 2003;125:1341-1354. (Pubitemid 37409754)
6. Leeb SN, Vogl D, Grossmann J, et al. Autocrine fibronectin-induced migration of human colonic fibroblasts. Am J Gastroenterol. 2004;99:335-340. (Pubitemid 38279878)
7. Leeb SN, Vogl D, Falk W, et al. Regulation of migration of human colonic myofibroblasts. Growth Factors. 2002;20:81-91. (Pubitemid 34823455)
8. Brenmoehl J, Miller SN, Hofmann C, et al. Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol. 2009;15:1431-1442.
9. Fine A, Goldstein RH. The effect of PGE2 on the activation of quiescent lung fibroblasts. Prostaglandins. 1987;33:903-913. (Pubitemid 18015867)
10. Goncharova EA, Billington CK, Irani C, et al. Cyclic AMP-mobilizing agents and glucocorticoids modulate human smooth muscle cell migration. Am J Resp Cell Mol Biol. 2003;29:19-27. (Pubitemid 36783312)
11. Ehrlich HP, Wyler DJ. Fibroblast contraction of collagen lattices in vitro: inhibition by chronic inflammatory cell mediators. J Cell Physiol. 1983;116:345-351.
12. Kawamoto M, Romberger DJ, Nakamura Y, et al. Modulation of fibroblast type I collagen and fibronectin production by bovine bronchial epithelial cells. Am J Resp Cell Mol Biol. 1995;12:425-433.
13. Kohyama T, Liu XD, Wen FQ, et al. Prostaglandin D2 inhibits fibroblast migration. Eur Respir J. 2002;19:684-689.
14. Kohyama T, Ertl RF, Valenti V, et al. Prostaglandin E(2) inhibits fibroblast chemotaxis. Am J Physiol. 2001;281:L1257-1263.
15. Sandulache VC, Parekh A, Li-Korotky HS, et al. Prostaglandin E2 differentially modulates human fetal and adult dermal fibroblast migration and contraction: implication for wound healing. Wound Repair Regen. 2006;14:633-643. (Pubitemid 44470082)
16. Sandulache VC, Parekh A, Li-Korotky H, et al. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen. 2007;15:122-133. (Pubitemid 46150985)
17. White ES, Atrasz RG, Dickie EG, et al. Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Resp Cell Mol Biol. 2005;32:135-141.
18. Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. Mucosal and plasma prostaglandin E2 in ulcerative colitis. Hepatogastroenterology. 1999;46:2338-2342. (Pubitemid 29454095)
19. Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. Effects of ulcerative colitis activity on plasma and mucosal prostaglandin E2 concentration. Prostaglandins Other Lipid Mediat. 1999;58:159-165. (Pubitemid 29518459)
20. Schmidt C, Baumeister B, Kipnowski J, et al. Alteration of prostaglandin E2 and leukotriene B4 synthesis in chronic inflammatory bowel disease. Hepatogastroenterology. 1996;43:1508-1512. (Pubitemid 27007341)
21. Koestler SA, Rottner K, Lai F, et al. F- and G-actin concentrations in lamellipodia of moving cells. PloS One. 2009;4:e4810.
22. Jester JV, Petroll WM, Barry PA, et al. Expression of alpha-smooth muscle (alpha-SM) actin during corneal stromal wound healing. Invest Ophthalmology Vis Sci. 1995;36:809-819.
23. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol. 2008;24:462-468.
24. Suganuma H, Sato A, Tamura R, et al. Enhanced migration of fibroblasts derived from lungs with fibrotic lesions. Thorax. 1995;50:984-989.
25. Pontz BF, Albini A, Mensing H, et al. Pattern of collagen synthesis and chemotactic response of fibroblasts derived from mucopolysaccharidosis patients. Exp Cell Res. 1984;155:457-466. (Pubitemid 15216641)
26. Karryeva B, Kozlovskaia LV, McHedlishvili BV, et al. Chemotactic function of skin fibroblasts in patients with amyloidosis. Biull Eksp Biol Med. 1990;109:578-580.
27. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193-1226.
28. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002;109:883-893. (Pubitemid 34275109)
29. Nitta M, Hirata I, Toshina K, et al. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand J Immunol. 2002;56:66-75. (Pubitemid 35304377)
30. Jiang GL, Nieves A, Im WB, et al. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther. 2007;320:22-28. (Pubitemid 46025715)
31. Fine A, Poliks CF, Donahue LP, et al. The differential effect of prostaglandin E2 on transforming growth factor-beta and insulin-induced collagen formation in lung fibroblasts. J Biol Chem. 1989;264:16988-16991. (Pubitemid 19255526)
32. Skold CM, Liu XD, Zhu YK, et al. Glucocorticoids augment fibroblast-mediated contraction of collagen gels by inhibition of endogenous PGE production. Proc Assoc Am Physicians. 1999;111:249-258.
33. Chen L, Zhang JJ, Huang XY. cAMP inhibits cell migration by interfering with Rac-induced lamellipodium formation. J Biol Chem. 2008;283:13799-13805.
34. Nishikawa M, de Lanerolle P, Lincoln TM, et al. Phosphorylation of mammalian myosin light chain kinases by the catalytic subunit of cyclic AMP-dependent protein kinase and by cyclic GMP-dependent protein kinase. J Biol Chem. 1984;259:8429-8436. (Pubitemid 14090601)
35. Garcia JG, Davis HW, Patterson CE. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell Physiol. 1995;163:510-522.
36. Spudich JA. In pursuit of myosin function. Cell Regul. 1989;1:1-11.
37. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and non-muscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325-1358.
38. Chew TL, Wolf WA, Gallagher PJ, et al. A fluorescent resonant energy transfer-based biosensor reveals transient and regional myosin light chain kinase activation in lamella and cleavage furrows. J Cell Biol. 2002;156:543-553.
39. Small JV, Stradal T, Vignal E, et al. The lamellipodium: where motility begins. Trends Cell Biol. 2002;12:112-120.
40. Huang S, Wettlaufer SH, Hogaboam C, et al. Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol. 2007;292:L405-413.
41. Laudanna C, Campbell JJ, Butcher EC. Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J Biol Chem. 1997;272:24141-24144. (Pubitemid 27418609)
42. Fleming YM, Frame MC, Houslay MD. PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration. J Cell Sci. 2004;117:2377-2388.
43. Diviani D, Soderling J, Scott JD. AKAP-Lbc anchors protein kinase A and nucleates Galpha 12-selective Rho-mediated stress fiber formation. J Biol Chem. 2001;276:44247-44257.